Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study
Blood (2012)
  • Matthew S. Davids, Harvard University
  • Andrew W. Roberts, Royal Melbourne Hospital
  • Mary Ann Anderson, Royal Melbourne Hospital
  • John M. Pagel, University of Washington
  • Brad S. Kahl, University of Wisconsin-Madison
  • John F. Gerecitano, Memorial Sloan Kettering Cancer Center
  • David E. Darden
  • Cathy E. Nolan
  • Lori A. Gressick
  • Jianning Yang
  • Brenda J. Chyla, Gulf Coast Regional Blood Center
  • Todd A. Busman, Walter and Eliza Hall Institute of Medical Research
  • Alison M. Graham
  • Elisa Cerri, University of Chicago
  • Sari H. Enschede, Rush University Medical Center
  • Rod A. Humerickhouse, Roswell Park Cancer Institute
  • John F. Seymour, Peter MacCallum Cancer Centre
Link
Disciplines
Publication Date
November 16, 2012
Citation Information
Matthew S. Davids, Andrew W. Roberts, Mary Ann Anderson, John M. Pagel, et al.. "The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study" Blood Vol. 120 Iss. 21 (2012) p. 304 - 304
Available at: http://works.bepress.com/john-pagel/140/